HIV Diagnostics Market Size Worth USD 5,396.32 Million by 2034 | CAGR: 7.6%

The global HIV diagnostics market size is expected to reach USD 5,396.32 million by 2034, according to a new study by Polaris Market Research. The report “HIV Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Product (Consumables, Instruments, and Software and Services), Mode, Test Type, End Use, and Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The HIV diagnostics market encompasses a range of advanced technologies and testing methodologies designed to detect, monitor, and manage HIV infections across different stages. The market is experiencing robust expansion, driven by the increasing prevalence of HIV infections, rising awareness about early detection, and government-led initiatives promoting universal screening programs. Advancements in molecular diagnostics, rapid point-of-care (POC) testing, and AI-driven analytics are transforming HIV diagnostics market trends, enhancing the accuracy, efficiency, and accessibility of testing solutions. The growing emphasis on self-testing kits and decentralized diagnostic models is further contributing to market growth, particularly in low-resource settings where traditional laboratory infrastructure is limited.

The HIV diagnostics market demand is accelerating due to expanding government funding, strategic collaborations with nonprofit organizations, and rising investments in R&D for next-generation testing technologies. Increasing adoption of automated nucleic acid amplification tests (NAATs), antigen-antibody combination assays, and biosensor-based diagnostics is strengthening market value, ensuring early detection and effective disease management. The integration of digital health platforms, AI-powered diagnostic tools, and cloud-based data management is reshaping industry trends, enabling real-time disease surveillance and personalized treatment planning.

Do you have questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/hiv-diagnostics-market/request-for-sample

The HIV diagnostics market opportunity is expanding through public-private partnerships, regulatory support for innovative testing solutions, and the development of high-throughput screening platforms capable of handling large-scale testing requirements. The emergence of cost-effective, portable diagnostic devices is further contributing to market expansion, particularly in resource-constrained regions. The increasing focus on precision medicine, rapid result turnaround, and scalable diagnostic models is driving market dynamics, fostering technological advancements and competitive differentiation. The demand for high-sensitivity, multiplexed diagnostic platforms is expected to remain strong, ensuring long-term HIV diagnostics market growth through continuous innovations and strategic market penetration efforts.

HIV Diagnostics Market Report Highlights

• In terms of product, the consumables segment dominated the HIV diagnostics market share in 2024 due to the high demand for reagents, test kits, and assay consumables across diagnostic laboratories.
• Based on end use, the diagnostic laboratories segment accounted for the largest market share in 2024 due to the widespread adoption of advanced HIV diagnostic technologies and centralized testing models.
• In 2024, North America accounted for the largest market share due to high testing rates and well-established healthcare infrastructure.
• Asia Pacific is expected to register the highest CAGR during the forecast period due to increasing awareness initiatives, expansion of ART coverage, and technological advancements.
• A few of the global key market players are Abbott; Apogee Flow Systems; BD; Beckman Coulter, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Janssen Global Services, LLC; Merck & Co. Inc.; Mylan N.V.; Point Care; QIAGEN; Siemens Healthcare GmbH; Sysmex Europe SE; VIIV Healthcare; and Zyomtronix, Inc.

Polaris Market Research has segmented the HIV diagnostics market report on the basis of product, mode, test type, end use, and region:

By Product Outlook (Revenue, USD Million, 2020–2034)

• Consumables
• Instruments
• Software and Services

By Mode Outlook (Revenue, USD Million, 2020–2034)

• Self-Test
• Lab-Based

By Test Type Outlook (Revenue, USD Million, 2020–2034)

• Antibody Test
• HIV-1 Screening Tests
• HIV-1 Antibody Confirmatory Tests
• HIV-2 & Group O Diagnostic Tests
• Viral Load Test
• CD4 Test
• Others

By End Use Outlook (Revenue, USD Million, 2020–2034)

• Diagnostic Laboratories
• Hospitals & Clinics
• Home Settings

By Regional Outlook (Revenue, USD Million, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

HIV Diagnostics Market Report Scope